View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

NextEra Energy, Inc.: Update to credit analysis

Our credit view of NEE reflects its size as a large utility holding company, credit supportive Florida regulation, a leading position in renewables and stable financial profile

 PRESS RELEASE

Virtu Financial Recognized Across Multiple Categories at the 2025 Lead...

Virtu Financial Recognized Across Multiple Categories at the 2025 Leaders in Trading Awards NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, is proud to announce that Virtu Financial received recognition in seven categories at the 2025 TRADE Awards in New York and London. Virtu Financial was honored in London with TCA Provider of the Year and Best Dark Pool Capabilities, and in N...

 PRESS RELEASE

America’s Car-Mart, Inc. Schedules Second Quarter Fiscal Year 2026 Res...

America’s Car-Mart, Inc. Schedules Second Quarter Fiscal Year 2026 Results and Conference Call ROGERS, Ark., Nov. 20, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2026 second quarter financial results on Thursday, December 4, 2025, before the market opens. A webcast and conference call will be held that same day at 9:00 a.m. ET to review the Company’s results. Participants may access the conference call via webcast using this link: . To participate via telephone, please register in advance using this . Upon registration, all tele...

 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...

 PRESS RELEASE

Virtu Financial Congratulates 2025 Women in Finance Award Recipients G...

Virtu Financial Congratulates 2025 Women in Finance Award Recipients Gabriella Gambino and Julie Feng NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE:VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to the global markets, is proud to announce that Gabriella Gambino and Julie Feng have been recognized at the Markets Media’s Women in Finance Americas Awards. Gabriella Gambino, recipient of the Rising Star award, has established herself as a versatile ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

America’s Car-Mart Closes $300 Million Term Loan to Enhance Capital St...

America’s Car-Mart Closes $300 Million Term Loan to Enhance Capital Structure ROGERS, Ark., Oct. 30, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“Car-Mart” or the “Company”) today announced the closing of a new five-year, $300 million funded term loan facility provided by funds managed by Silver Point Capital, L.P. In connection with this transaction, the Company fully repaid the outstanding balance under its asset-backed line of credit (ABL), simplifying its balance sheet and creating a more flexible and scalable capital structure to support long-term growth oppo...

 PRESS RELEASE

OPKO Health Reports Third Quarter 2025 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration wi...

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...

 PRESS RELEASE

Virtu Announces Third Quarter 2025 Results

Virtu Announces Third Quarter 2025 Results NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NYSE: VIRT), a leading provider of financial services and products that leverages cutting edge technology to deliver innovative, transparent trading solutions to its clients and liquidity to the global markets, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025: Net income of $149.1 million; Normalized Adjusted Net Income1 of $166.5 millionBasic and diluted earnings per share of $0.86; Normalized Adjusted EPS1 of $1.05Total revenues of $824...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for ...

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial () with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch